In order to expand its already obscene profit streams, New York-based pharmaceutical giant Bristol-Myers Squibb is partnering with Tsinghua University in communist China to develop new drugs for novel cancers and autoimmune diseases.
This is problematic because Tsinghua University has a "clear connection" to the Chinese Communist Party (CCP). The school has also launched cyberattacks against the United States, and thus represents a threat to national security, according to the U.S. Department of State. (Related: Tsinghua University is also a CCP propaganda training ground, we now know.)
Current CCP leader Xi Jinping claimed Tsinghua University as his alma mater, which in part explains the school's "Marxist" journalism school, which is training the next generation of Chinese-run state media propagandists on how to deceive Chinese people along with the rest of the world.
The New York Times, CNN and other corporate-controlled media outlets throughout the West reportedly assist Tsinghua University's journalism school with training propagandists, many of whom now work for these very same Western media outlets.
Big Pharma represents everything that is evil and wrong with the world
Because of the work it carries out for communist China's military, Tsinghua University has been flagged as a "very high risk" school that has no business working with Bristol-Myers Squibb or any other drug cartel player – although it makes perfect sense that the two are partners.
Pharmaceuticals are, of course, a Deep State tool for brainwashing and depopulation. Many pharmaceutical drugs are linked to brain damage and mind control, allowing those who use them to be influenced and even steered to behave and think according to the agenda of the powers that be.
According to the agreement that was forged, Tsinghua University's Innovation Center for Immune Therapy will develop therapeutics that Bristol-Myers Squibb will then have the option to license.
It turns out that Bristol-Myers Squibb partnered with Tsinghua University back in 2013 for autoimmune target discovery and structural biology, and this is just an expansion of that collaborative research effort.
In a press release, Carl Decicco, senior vice president and head of discovery at Bristol-Myers Squibb, praised Tsinghua University and the communist regime it represents, as well as celebrated what is soon to come for the two entities.
"Tsinghua University is a highly respected research institution with leading capabilities and scientific talent focused on accelerating basic research into potential new therapies," Decicco said. "We look forward to bringing projects forward that will benefit from their innovative research in immunology and autoimmune disease."
Shirley Zhao, general manager and president of Bristol-Myers Squibb in mainland China and Hong Kong, also issued a statement celebrating this strategic partnership, which has the potential to generate untold billions in new profits.
"This collaboration with Tsinghua University is another proof of our strategic alignment with China's innovation-driven healthcare development, as well as our commitment to accelerate delivering of innovative treatment options to Chinese patients," she said.
The news is chilling in light of the fact that there is still considerable controversy over other ties between Big Pharma and communist China that many now believe is responsible for the unleashing of the Wuhan coronavirus (COVID-19).
Tony Fauci and other criminal career politicians and establishment figures forged key partnership with various communist Chinese entities that then worked on producing bioweapons from bat coronaviruses and other pathogens.
Evidence is also emerging to suggest that Ukraine and its many U.S.-run biolabs were also involved, hence why the establishment is so upset that Vladimir Putin decided to launch his "special operation" in Ukraine, presumably to clean out the place of all that corrupt filth.
Want to keep up with the latest news about Big Pharma's treasonous partnership with communist China? You can do so at Treason.news.
Sources for this article include:
Please contact us for more information.